Current Psychiatry Reports

, Volume 14, Issue 6, pp 650–658 | Cite as

Obesity in Bipolar Disorder: An Overview

  • Susan L. McElroyEmail author
  • Paul E. KeckJr
Bipolar Disorders (MA Frye, Section Editor)


Bipolar disorder (BD) is associated with obesity, overweight, and abdominal obesity, and BD individuals with obesity have a greater illness burden. Factors related to BD, its treatment, and the individual may all contribute to BD’s association with obesity. Management strategies for the obese BD patient include use of medications with better metabolic profiles, lifestyle interventions, and adjunctive pharmacotherapy for weight loss. Obesity-related psychiatric and medical comorbidities should also be assessed and managed. Bariatric surgery may be an option for carefully selected patients. Greater research into the theoretical underpinnings and clinical management of the BD-obesity connection is needed.


Bipolar disorder BD Obesity Co-occurrence Comorbid eating disorders Metabolic syndrome Binge eating disorder Weight management Diet Exercise Pharmacotherapy Bariatric surgery Psychiatry 



S. L. McElroy: board member of Alkermes and Shire; consultant for Eli Lilly and Company, Schering-Plough, and Shire; research funding from Agency for Healthcare Research and Quality (AHRQ), Abbot, Alkermes, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly and Company, Forest, GlaxoSmithKline, Jazz Pharmaceuticals, Marriott Foundation, National Institute of Mental Health, Orexigen Therapeutics, Shire, and Takeda Pharmaceuticals; and inventor on US Patent No. 6,323,236B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and along with the patent’s assignee, University of Cincinnati, Cincinnati, OH, receives payments from Johnson & Johnson, which has exclusive rights under the patent; P. E. Keck: consultant for Bristol-Myers Squibb, Pamlab, and Forest Labs.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    McElroy SL, Kotwal R, Malhotra S, et al. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry. 2004;65:634–51.PubMedCrossRefGoogle Scholar
  2. 2.
    McElroy SL. Obesity in patients with severe mental illness: Overview and management. J Clin Psychiatry. 2009;70 Suppl 3:12–21.PubMedCrossRefGoogle Scholar
  3. 3.
    De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10:52–77.Google Scholar
  4. 4.
    Taylor VH, McIntyre RS, Remington G, et al. Beyond pharmacotherapy: Understanding the links between obesity and chronic mental illness. Can J Psychiatry. 2012;57:5–12.PubMedGoogle Scholar
  5. 5.
    McIntyre RS, Alsuwaidan M, Goldstein BI, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry. 2012;24:69–81.PubMedGoogle Scholar
  6. 6.
    Bray GA. Obesity: The disease. J Med Chem. 2006;49:4001–7.PubMedCrossRefGoogle Scholar
  7. 7.
    National Institutes of Health. National Heart, Lung and Blood Institute: Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight in Adults: The Evidence Report. National Institutes of Health, Bethesda, MD, 1998.Google Scholar
  8. 8.
    World Health Organization: Obesity and overweight. Fact sheet N°311. Available via Accessed 12 Apr 2012.
  9. 9.
    de Koning L, Merchant AT, Pogue J, et al. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: Meta-regression analysis of prospective studies. Eur Heart J. 2007;28:850–6.PubMedCrossRefGoogle Scholar
  10. 10.
    de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA. 2001;285:2109–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 146 million white adults. N Engl J Med. 2010;363:2211–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Lee EB. Obesity, leptin, and Alzheimer’s disease. Ann N Y Acad Sci. 2011;1243:15–29.PubMedCrossRefGoogle Scholar
  13. 13.
    Guize L, Pannier B, Thomas F, et al. Recent advances in metabolic syndrome and cardiovascular disease. Arch Cardiovasc Dis. 2008;101:577–83.PubMedCrossRefGoogle Scholar
  14. 14.
    Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557–67.PubMedCrossRefGoogle Scholar
  15. 15.
    Ogden CL, Yanovski SZ, Carroll MD, et al. The epidemiology of obesity. Gastroenterology. 2007;132:2087–102.PubMedCrossRefGoogle Scholar
  16. 16.
    Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012;307:491–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Sturm R. Increases in morbid obesity in the USA: 2000–2005. Public Health. 2007;121:492–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Walls HL, Magliano DJ, McNeil JJ, et al. Predictors of increasing waist circumference in an Australian population. Public Health Nutr. 2011;14:870–81.PubMedCrossRefGoogle Scholar
  19. 19.
    •• McAllister EJ, Dhurandhar NV, Keith SW, et al. Ten putative contributors to the obesity epidemic. Crit Rev Food Sci Nutr. 2009;49:868–913. Excellent overview of potential factors contributing to the secular increase in obesity. PubMedCrossRefGoogle Scholar
  20. 20.
    Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry. 2003;64:1426–35.PubMedCrossRefGoogle Scholar
  21. 21.
    Sicras A, Rejas J, Navarro R, et al. Metabolic syndrome in bipolar disorder: A cross-sectional assessment of a Health Management Organization database. Bipolar Disord. 2008;10:607–16.PubMedCrossRefGoogle Scholar
  22. 22.
    Weber NS, Fisher JA, Cowan DN, et al. Psychiatric and general medical conditions comorbid with bipolar disorder in the National Hospital Discharge Survey. Psychiatr Serv. 2011;62:1152–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Goldstein BI, Birmaher B, Axelson DA, et al. Preliminary findings regarding overweight and obesity in pediatric bipolar disorder. J Clin Psychiatry. 2008;69:1953–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Kim B, Kim SJ, Son JI, et al. Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients. J Affect Disord. 2008;105:45–52.PubMedCrossRefGoogle Scholar
  25. 25.
    Maina G, Salvi V, Vitalucci A, et al. Prevalence and correlates of overweight in drug-naive patients with bipolar disorder. J Affect Disord. 2008;110:149–55.PubMedCrossRefGoogle Scholar
  26. 26.
    Alciati A, Gesuele F, Rizzi A, et al. Childhood parental loss and bipolar spectrum in obese bariatric surgery candidates. Int J Psychiatry Med. 2011;41:155–71.PubMedCrossRefGoogle Scholar
  27. 27.
    McIntyre RS, Konarski JZ, Wilkins K, et al. Obesity in bipolar disorder and major depressive disorder: Results from a national community health survey on mental health and well-being. Can J Psychiatry. 2006;51:274–80.PubMedGoogle Scholar
  28. 28.
    McIntyre RS, McElroy SL, Konarski JZ, et al. Substance use disorders and overweight/obesity in bipolar I disorder: Preliminary evidence for competing addictions. J Clin Psychiatry. 2007;68:1352–7.PubMedCrossRefGoogle Scholar
  29. 29.
    • Simon GE, Von Korff M, Saunders K, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry. 2006;63:824–30. One of the first epidemiologic studies to demonstrate the co-variation between BD and obesity. PubMedCrossRefGoogle Scholar
  30. 30.
    Goldstein BI, Liu SM, Zivkovic N, et al. The burden of obesity among adults with bipolar disorder in the United States. Bipolar Disord. 2011;13:387–95.PubMedCrossRefGoogle Scholar
  31. 31.
    Petry NM, Barry D, Pietrzak RH, et al. Overweight and obesity are associated with psychiatric disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med. 2008;70:288–97.PubMedCrossRefGoogle Scholar
  32. 32.
    Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844–50.PubMedCrossRefGoogle Scholar
  33. 33.
    Brietzke E, Kapczinski F, Grassi-Oliveira R, et al. Insulin dysfunction and allostatic load in bipolar disorder. Expert Rev Neurother. 2011;11:1017–28.PubMedCrossRefGoogle Scholar
  34. 34.
    Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. 2004;6:368–73.PubMedCrossRefGoogle Scholar
  35. 35.
    Fagiolini A, Kupfer DJ, Rucci P, et al. Suicide attempts and ideation in patients with bipolar I disorder. J Clin Psychiatry. 2004;65:509–14.PubMedCrossRefGoogle Scholar
  36. 36.
    Yim CY, Soczynska JK, Kennedy SH, et al. The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. Eur Psychiatry. 2012;27:223–8.PubMedCrossRefGoogle Scholar
  37. 37.
    • Fagiolini A, Kupfer DJ, Houck PR, et al. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003;160:112–7. The first prospective study to show an association between obesity and negative outcomes in BD. PubMedCrossRefGoogle Scholar
  38. 38.
    Bond DJ, Kunz M, Torres IJ, et al. The association of weight gain with mood symptoms and functional outcomes following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). Bipolar Disord. 2010;12:616–26.PubMedCrossRefGoogle Scholar
  39. 39.
    •• Goldstein BI, Kemp DE, Soczynska JK, et al. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: A systematic review of the literature. J Clin Psychiatry. 2009;70:1078–90. Excellent synthesis of the potential role inflammation plays in the relationship between BD and obesity. PubMedCrossRefGoogle Scholar
  40. 40.
    Bond DJ, Lang DJ, Noronha MM, et al. The association of elevated body mass index with reduced brain volumes in first-episode mania. Biol Psychiatry. 2011;70:381–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Torrent C, Amann B, Sanchez-Moreno J, et al. Weight gain in bipolar disorder: Pharmacological treatment as a contributing factor. Acta Psychiatr Scand. 2008;118:4–18.PubMedCrossRefGoogle Scholar
  42. 42.
    Lipkovich I, Citrome L, Perlis R, et al. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol. 2006;26:316–20.PubMedCrossRefGoogle Scholar
  43. 43.
    McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry. 2002;63:207–13.PubMedCrossRefGoogle Scholar
  44. 44.
    McElroy SL, Frye MA, Hellemann G, et al. Prevalence and correlates of eating disorders in 875 patients with bipolar disorder. J Affect Disord. 2011;128:191–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Barry D, Pietrzak RH, Petry NM. Gender differences in associations between body mass index and DSM-IV mood and anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Ann Epidemiol. 2008;18:458–66.PubMedCrossRefGoogle Scholar
  46. 46.
    Elmslie JL, Mann JI, Silverstone JT, et al. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry. 2001;62:486–91.PubMedCrossRefGoogle Scholar
  47. 47.
    Fleet-Michaliszyn SB, Soreca I, Otto AD, et al. A prospective observational study of obesity, body composition, and insulin resistance in 18 women with bipolar disorder and 17 matched control subjects. J Clin Psychiatry. 2008;69:1892–900.PubMedCrossRefGoogle Scholar
  48. 48.
    Delgado-Rico E, Rio-Valle JS, Gonzalez-Jimenez E, et al. BMI predicts emotion-driven impulsivity and cognitive inflexibility in adolescents with excess weight. Obesity (Silver Spring). 2012;20:1604–10.CrossRefGoogle Scholar
  49. 49.
    Fernandes BS, Gama CS, Cereser KM, et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2011;45:995–1004.PubMedCrossRefGoogle Scholar
  50. 50.
    Cordeira J, Rios M. Weighing in the role of BDNF in the central control of eating behavior. Mol Neurobiol. 2011;44:441–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Anand A, Barkay G, Dzemidzic M, et al. Striatal dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disord. 2011;13:406–13.PubMedCrossRefGoogle Scholar
  52. 52.
    Carlson PJ, Merlock MC, Suppes T. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord. 2004;6:416–20.PubMedCrossRefGoogle Scholar
  53. 53.
    Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161:564–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Zarate Jr CA, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004;56:54–60.PubMedCrossRefGoogle Scholar
  55. 55.
    Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007;164:1242–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Calabrese JR, Ketter TA, Youakim JM, et al. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2010;71:1363–70.PubMedCrossRefGoogle Scholar
  57. 57.
    Finger BC, Dinan TG, Cryan JF. High-fat diet selectively protects against the effects of chronic social stress in the mouse. Neuroscience. 2011;192:351–60.PubMedCrossRefGoogle Scholar
  58. 58.
    Yamada N, Katsuura G, Ochi Y, et al. Impaired CNS leptin action is implicated in depression associated with obesity. Endocrinology. 2011;152:2634–43.PubMedCrossRefGoogle Scholar
  59. 59.
    Black DW, Goldstein RB, Mason EE, et al. Depression and other mental disorders in the relatives of morbidly obese patients. J Affect Disord. 1992;25:91–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Grucza RA, Krueger RF, Racette SB, et al. The emerging link between alcoholism risk and obesity in the United States. Arch Gen Psychiatry. 2010;67:1301–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Heber D, Carpenter CL. Addictive genes and the relationship to obesity and inflammation. Mol Neurobiol. 2011;44:160–5.PubMedCrossRefGoogle Scholar
  62. 62.
    De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011;10:138–51.PubMedGoogle Scholar
  63. 63.
    Ahmed AT, Blair TR, McIntyre RS. Surgical treatment of morbid obesity among patients with bipolar disorder: A research agenda. Adv Ther. 2011;28:389–400.PubMedCrossRefGoogle Scholar
  64. 64.
    Mark AL. Dietary therapy for obesity: An emperor with no clothes. Hypertension. 2008;51:1426–34.PubMedCrossRefGoogle Scholar
  65. 65.
    Rejeski WJ, Ip EH, Bertoni AG, et al. Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med. 2012;366:1209–17.PubMedCrossRefGoogle Scholar
  66. 66.
    Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, et al. Non-pharmacological management of antipsychotic-induced weight gain: Systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2008;193:101–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev. 2007:CD005148.Google Scholar
  68. 68.
    Gillhoff K, Gaab J, Emini L, et al. Effects of a multimodal lifestyle intervention on body mass index in patients with bipolar disorder: a randomized controlled trial. Prim Care Companion J Clin Psychiatry. 2010;12:pii.Google Scholar
  69. 69.
    Sarris J, Mischoulon D, Schweitzer I. Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: A systematic review of clinical trials. Bipolar Disord. 2011;13:454–65.PubMedCrossRefGoogle Scholar
  70. 70.
    Kwak SM, Myung SK, Lee YJ, et al. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: A meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med. 2012;172:686–94.Google Scholar
  71. 71.
    Milaneschi Y, Bandinelli S, Penninx BW, et al. Depressive symptoms and inflammation increase in a prospective study of older adults: A protective effect of a healthy (Mediterranean-style) diet. Mol Psychiatry. 2011;16:589–90.PubMedCrossRefGoogle Scholar
  72. 72.
    Elmslie JL, Porter RJ, Joyce PR, et al. Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet. Bipolar Disord. 2006;8:503–7.PubMedCrossRefGoogle Scholar
  73. 73.
    Malik VS, Hu FB. Sweeteners and risk of obesity and type 2 diabetes: The role of sugar-sweetened beverages. Curr Diab Rep. 2012;12:195–203.Google Scholar
  74. 74.
    Richardson CR, Faulkner G, McDevitt J, et al. Integrating physical activity into mental health services for persons with serious mental illness. Psychiatr Serv. 2005;56:324–31.PubMedCrossRefGoogle Scholar
  75. 75.
    Alsuwaidan MT, Kucyi A, Law CW, et al. Exercise and bipolar disorder: A review of neurobiological mediators. Neuromolecular Med. 2009;11:328–36.PubMedCrossRefGoogle Scholar
  76. 76.
    Sylvia LG, Ametrano RM, Nierenberg AA. Exercise treatment for bipolar disorder: potential mechanisms of action mediated through increased neurogenesis and decreased allostatic load. Psychother Psychosom. 2010;79:87–96.PubMedCrossRefGoogle Scholar
  77. 77.
    Poulin MJ, Chaput JP, Simard V, et al. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust N Z J Psychiatry. 2007;41:980–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Wright K, Armstrong T, Taylor A, et al. ‘It’s a double edged sword’: A qualitative analysis of the experiences of exercise amongst people with bipolar disorder. J Affect Disord. 2012;136:634–42.PubMedCrossRefGoogle Scholar
  79. 79.
    Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: A systematic review and meta-analysis. Neuropsychopharmacology. 2010;35:1520–30.PubMedCrossRefGoogle Scholar
  80. 80.
    Agarwal SM, Behere RV, Venkatasubramanian G, et al. A case of successful treatment of comorbid obesity and polycystic ovarian disease with add-on metformin in bipolar disorder. Prim Care Companion CNS Disord. 2011;13:pii.Google Scholar
  81. 81.
    McElroy SL, Guerdjikova AI, Mori N, et al. Pharmacolgical management of binge eating disorder: Current and emerging treatment options. Ther Clin Risk Manag. 2012;8:219–41.PubMedCrossRefGoogle Scholar
  82. 82.
    Tchoukhine E, Takala P, Hakko H, et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: A 16-week open-label extension phase and both phases of a randomized controlled trial. J Clin Psychiatry. 2011;72:326–30.PubMedCrossRefGoogle Scholar
  83. 83.
    Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: Past, current, and future therapies. J Obes. 2011;2011:179674.PubMedGoogle Scholar
  84. 84.
    Merideth CH. A single-center, double-blind, placebo-controlled evaluation of lamotrigine in the treatment of obesity in adults. J Clin Psychiatry. 2006;67:258–62.PubMedCrossRefGoogle Scholar
  85. 85.
    Kushner SF, Khan A, Lane R, et al. Topiramate monotherapy in the management of acute mania: Results of four double-blind placebo-controlled trials. Bipolar Disord. 2006;8:15–27.PubMedCrossRefGoogle Scholar
  86. 86.
    Roy Chengappa KN, Schwarzman LK, Hulihan JF, et al. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: A randomized, placebo-controlled trial. J Clin Psychiatry. 2006;67:1698–706.PubMedCrossRefGoogle Scholar
  87. 87.
    Roy Chengappa K, Kupfer DJ, Parepally H, et al. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Bipolar Disord. 2007;9:609–17.PubMedCrossRefGoogle Scholar
  88. 88.
    McIntyre RS, Mancini DA, McCann S, et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: A preliminary single-blind study. Bipolar Disord. 2002;4:207–13.PubMedCrossRefGoogle Scholar
  89. 89.
    McElroy SL, Winstanley E, Mori N, et al. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain. J Clin Psychopharmacol. 2012;32:165–72.PubMedCrossRefGoogle Scholar
  90. 90.
    Bowden CL, Calabrese JR, Ketter TA, et al. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry. 2006;163:1199–201.PubMedCrossRefGoogle Scholar
  91. 91.
    Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev. 2007;59:151–84.PubMedCrossRefGoogle Scholar
  92. 92.
    Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60:1079–88.PubMedCrossRefGoogle Scholar
  93. 93.
    Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care. 1996;19:667–70.PubMedCrossRefGoogle Scholar
  94. 94.
    Henderson DC, Freudenreich O, Borba CP, et al. Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. Schizophr Res. 2011;130:53–6.PubMedCrossRefGoogle Scholar
  95. 95.
    Via MA, Chandra H, Araki T, et al. Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2010;3:43–8.PubMedCrossRefGoogle Scholar
  96. 96.
    Graham KA, Gu H, Lieberman JA, et al. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry. 2005;162:1744–6.PubMedCrossRefGoogle Scholar
  97. 97.
    Deberdt W, Winokur A, Cavazzoni PA, et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol. 2005;15:13–21.PubMedCrossRefGoogle Scholar
  98. 98.
    Semanscin-Doerr DA, Windover A, Ashton K, et al. Mood disorders in laparoscopic sleeve gastrectomy patients: Does it affect early weight loss? Surg Obes Relat Dis. 2010;6:191–6.PubMedCrossRefGoogle Scholar
  99. 99.
    Steinmann WC, Suttmoeller K, Chitima-Matsiga R, et al. Bariatric surgery: 1-year weight loss outcomes in patients with bipolar and other psychiatric disorders. Obes Surg. 2011;21:1323–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Lindner Center of HOPEMasonUSA
  2. 2.Department of Psychiatry and Behavioral NeuroscienceUniversity of Cincinnati College of MedicineCincinnatiUSA

Personalised recommendations